1. Opening Hook
Global agchem is in a hangover phase, Chinese factories won’t stop producing, rains won’t behave, and distributors are allergic to inventory. In this chaos, PI Industries calmly tells investors: “Relax, recovery is scheduled—just not today.”
Q2 FY26 looked ugly on the topline, respectable on margins, and ambitious in narrative. Revenues fell sharply, yet EBITDA margins refused to blink. Meanwhile, management spoke confidently about biologicals, pharma CRDMO, electronic chemicals, and molecules that won’t make money until your patience runs out.
This concall wasn’t about numbers—it was about conviction. The kind that says: “Yes, we’re hurting now, but trust us, FY27 is where the party starts.”
Stick around. The optimism-to-execution gap is where things get interesting.
2. At a Glance
- Revenue down 16% YoY – High base, bad weather, and global destocking teamed up.
- H1 revenue down 12% – Still beats industry, management insists smugly.
- EBITDA margin ~28–29% – Topline weak, but product mix saved the day.
- New products up 38% YoY (H1) – Old molecules sulk, new ones hustle.
- Working capital at 113 days – Customers delaying, PI politely waiting.
3. Management’s Key Commentary
“Global crop protection is passing through a prolonged down-cycle.”
(Translation: Everyone’s hurting, not just us.)
“FY26 may see recovery only from Q4; full recovery post H2 2026.”
(Translation: Don’t ask for miracles before FY27 😏)
“We commercialised five new molecules in H1 and plan 8–10 this year.”
(Translation: Pipeline strong, revenue will catch up… someday.)
“Domestic performance was impacted by erratic rains and regulatory changes.”
(Translation: Blame clouds and babus.)
“Pharma revenues grew 54% YoY.”
(Translation: Small base, big ambitions.)
“Biologicals are the next growth driver for the industry.”
(Translation: Chemicals are passé, peptides are cool now.)
